News | December 07, 2021
RDIF offers vaccine for adolescents aged 12-17 in India
Sputnik M is a new member of the Sputnik vaccines family
Sputnik M is a new member of the Sputnik vaccines family
According to the Russian Direct Investment Fund (RDIF), the Russian Sputnik V and Sputnik Light vaccines have proven to be highly effective against all variants of SARC-Cov-2
Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik
AstraZeneca, Sinopharm and Moderna were part of the study
The first batch will be shipped to the Gamaleya Center for the quality control
First batch produced at Panacea Biotec’s facilities at Baddi will be shipped to the Gamaleya Center for quality control and full scale production of the vaccine is due to start this summer
Production of Sputnik V at Panacea Biotec sites will help facilitate global supply of Sputnik V to international partners of RDIF
The Phase 2 study of Sputnik V was conducted on 100 subjects as part of the randomized, double-blind, parallel-group, placebo-controlled study in India.
Subscribe To Our Newsletter & Stay Updated
